Johnson & Johnson: Prostatic Neoplasms trials

The registry lists 88 Prostatic Neoplasms studies with Johnson & Johnson as lead sponsor. 7 are open to participants now and 29 have results posted.

Phase 1 32Phase 2 25Phase 3 14Phase 4 2No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-101556143 in Participants With Metastatic Prostate CancerRecruitingNCT07832292Phase 2
• A Study of JNJ-98768111 in Participants With Advanced Prostate CancerRecruitingNCT07746713Phase 1
• A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in FranceRecruitingNCT07451002
• A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerRecruitingNCT07319871Phase 1
• A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate CancerRecruitingNCT07082920Phase 1
• Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerRecruitingNCT06800313Phase 1/2
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingNCT06095089Phase 1
• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesCompletedNCT04523207Phase 2Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)Active, not recruitingNCT04497844Phase 3Results posted
• A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)CompletedNCT04108208Phase 4Results posted
• An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesCompletedNCT02854436Phase 2Results posted
• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCActive, not recruitingNCT02489318Phase 3Results posted
• An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingNCT02257736Phase 3Results posted
• Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol TherapyCompletedNCT02217566Phase 2Results posted
• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT01946204Phase 3Results posted
• Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to ChemotherapyCompletedNCT01867710Phase 2Results posted
• The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate CancerCompletedNCT01790126Phase 2Results posted
• A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)CompletedNCT01715285Phase 3Results posted
• A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based ChemotherapyCompletedNCT01695135Phase 3Results posted
• A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate CancerCompletedNCT01685983Phase 2Results posted
• A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone AcetateCompletedNCT01517802Phase 3Results posted
• A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01424930Phase 2Results posted
• IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific AntigenCompletedNCT01314118Phase 2Results posted
• Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)CompletedNCT01171898Phase 1/2Results posted
• Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate CancerCompletedNCT01088529Phase 2Results posted
• A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate CancerCompletedNCT00992186Phase 2Results posted
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate CancerCompletedNCT00924469Phase 2Results posted
• Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT00887198Phase 3Results posted
• Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT00638690Phase 3Results posted
• An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow PlasmaCompletedNCT00544440Phase 2Results posted
• An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00537381Phase 2Results posted
• An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyCompletedNCT00485303Phase 2Results posted
• An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyCompletedNCT00474383Phase 2Results posted
• Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate CancerCompletedNCT00473746Phase 1/2Results posted
• A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone TherapyCompletedNCT00473512Phase 1/2Results posted
• A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)TerminatedNCT00385827Phase 2Results posted
• A Study of JNJ-80038114 in Participants With Advanced Stage Prostate CancerCompletedNCT05441501Phase 1
• Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)Approved for marketingNCT05401214
• A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal TherapyCompletedNCT05303558
• A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)TerminatedNCT05295927Phase 1
• A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer ParticipantsCompletedNCT05022849Phase 1
• A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate CancerActive, not recruitingNCT04898634Phase 1
• ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerActive, not recruitingNCT04662580Phase 1
• A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerActive, not recruitingNCT04644770Phase 1
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingNCT04577833Phase 1
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerActive, not recruitingNCT04557059Phase 3
• A Study of JNJ-70218902 in Participants With Advanced Stage Solid TumorsCompletedNCT04397276Phase 1
• A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With DiethylstilbestrolCompletedNCT04268628
• A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in JapanCompletedNCT04034095
• A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerCompletedNCT03871816
• A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyActive, not recruitingNCT03767244Phase 3
• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT03551782Phase 1
• A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03523442Phase 1
• An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate CancerNo longer availableNCT03523338
• A Study of Participants With Advanced Prostate Cancer in CanadaCompletedNCT03501173
• A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
• A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerWithdrawnNCT02906605Phase 2
• A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)WithdrawnNCT02905201
• A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer ParticipantsCompletedNCT02813408
• Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) TolerabilityCompletedNCT02663193
• Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate CancerCompletedNCT02625857Phase 1
• A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate CancerWithdrawnNCT02608359
• A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc StudyCompletedNCT02578797Phase 1
• A Registry of Participants With Prostate Cancer in AsiaCompletedNCT02546908
• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingNCT02531516Phase 3
• A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyCompletedNCT02405858Phase 4
• A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology SettingCompletedNCT02364531
• A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical CareCompletedNCT02236637
• Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)CompletedNCT02230059
• A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02123758Phase 1
• A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionCompletedNCT02001571Phase 1
• A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNo longer availableNCT01834209
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received DocetaxelCompletedNCT01795703Phase 2
• Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone AcetateCompletedNCT01792687Phase 1
• A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate CancerCompletedNCT01756638Phase 2
• Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate CancerWithdrawnNCT01692483
• An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001CompletedNCT01664728Phase 1
• Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate CancerCompletedNCT01591122Phase 3
• A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)CompletedNCT01400555Phase 1
• Study of Abiraterone Acetate in Patients With Advanced Prostate CancerApproved for marketingNCT01217697
• Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate CancerCompletedNCT01186484Phase 1
• A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01017939Phase 1
• A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT00910754Phase 1
• A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate CancerCompletedNCT00600535Phase 1
• A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00401765Phase 1
• Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.CompletedNCT00364455Phase 3
• A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate CancerCompletedNCT00072670Phase 2